Taketoshi Nara

965 citations
42 papers · 277 indexed · h-index 10
Topics
Renal cell carcinoma treatment (15 papers)Bladder and Urothelial Cancer Treatments (7 papers)Cancer, Lipids, and Metabolism (6 papers)
Journals
SHILAP Revista de lepidopterologíaPLoS ONEScientific Reports
Partner nations
Japan

In The Last Decade

Taketoshi Nara

35 papers receiving 275 citations

Peers

Taketoshi Nara
Comparison fields: 5 of 49
  • Pulmonary and Respiratory Medicine 151
  • Molecular Biology 83
  • Oncology 78
  • Cancer Research 64
  • Surgery 43
Replace Fucai Tang with:
Fucai Tang China
Shinsuke Kurokawa Japan
Liefu Ye China
Xiao Zheng China
Honggang Qi China
Gang Zhu China
Fengbin Gao China
Dexin Dong China
Shuqiu Chen China
Taketoshi Nara relative to Fucai Tang China Fucai Tang's profile →
Citations per field
00.5×
Fucai Tang · 1×
Citations per year

Countries citing papers authored by Taketoshi Nara

Since Specialization
Citations

This map shows the geographic impact of Taketoshi Nara's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Taketoshi Nara with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Taketoshi Nara more than expected).

Fields of papers citing papers by Taketoshi Nara

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Taketoshi Nara. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Taketoshi Nara. The network helps show where Taketoshi Nara may publish in the future.

Co-authorship network of co-authors of Taketoshi Nara

This figure shows the co-authorship network connecting the top 25 collaborators of Taketoshi Nara. A scholar is included among the top collaborators of Taketoshi Nara based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Taketoshi Nara. Taketoshi Nara is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 2
2 3
3 0
4 0
5 10
6 2
7 20
8 0
9 5
10 3
11 0
12 10
13 3
14 1
15 3
16 3
17 11
18 33
19 13
20 2

About Taketoshi Nara

Taketoshi Nara is a scholar working on Pulmonary and Respiratory Medicine, Transplantation and Cancer Research, having authored 42 papers that have together received 277 indexed citations. Recurring topics across this work include Renal cell carcinoma treatment (15 papers), Bladder and Urothelial Cancer Treatments (7 papers) and Cancer, Lipids, and Metabolism (6 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (151 citations), Cancer Research (64 citations) and Oncology (78 citations). Taketoshi Nara has collaborated with scholars based in Japan. Frequent co-authors include Tomonori Habuchi, Shintaro Narita, Takamitsu Inoue, Atsushi Koizumi, Kazuyuki Numakura, Mitsuru Saito, Mingguo Huang, Shigeru Satoh, Norihiko Tsuchiya and Hiromi Sato. Their work appears in journals such as SHILAP Revista de lepidopterología, PLoS ONE and Scientific Reports.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026